ETTEvac
DeviceEndotracheal tube with evacuation lumen without noble metal coating
NCT Number: NCT04242706
The study objective is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard coating. The study is randomized, prospective, controlled and blinded. All adult patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Centre Hospitalier Chrétien de Liège and Centre Hospitalier Chrétien (CHC Clinique de l'Espérance), Liège, Belgium
The aim of the study is to determine VAP (Ventilator Associated Pneumonia) baseline incidence in the ICU in patients receiving endotracheal tubes with evacuation lumen with and without Bactiguard Infection Protection (BIP) coating.
VAP is likely to occur in 10-20% of patients who are ventilated for at least 48 hours. These patients face a mortality risk estimated to be twice as high compared with similar ICU patients without VAP. Furthermore, VAP results in an average excess length of ICU stay with high hospital cost.
Bactiguard has developed an endotracheal tube coated with a thin layer of non-releasing metals (gold, silver and palladium) firmly attached to the surface. This Bactiguard coating is tissue friendly and aims to achieve an optimal combination of anti-infective properties to reduce biofilm formation, colonization and subsequent respiratory infection. Bactiguard coated urinary products have been on market since 1995 (initially in US, then also in Japan & Europe) and used in a large number of clinical studies and evaluations, showing reduction of urinary tract infections and also antibiotics use. A BIP ETT (without evacuation lumen) clinical safety and tolerability study was performed at Karolinska University Hospital during 20128. The study showed that BIP ETT is safe, well tolerable and performs well in clinical settings.
The present study of BIP ETT with evacuation lumen is randomized, prospective, controlled and blinded. All adult ICU patients hospitalized in the ICUs from two tertiary hospitals (i.e.: Centre Hospitalier Universitaire Sart Tilman Liège , Centre Hospitalier Chrétien de Liège) and considered to be ventilated for more than 24 hours will be eligible to participate in the study. 300 patients in total will be used to determine baselines levels (150 in each group).
The study tubes will be available not only in the ICUs but also in the emergency department, including the emergency vehicles, and in every hospital wards. The study tubes will not be available in the operating rooms except in the Post Anesthesia Care Units (PACU) and Recovery rooms.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Endotracheal tube with evacuation lumen without noble metal coating
Endotracheal tube with evacuation lumen with noble metal coating
Time frame: Up to 28 days after inclusion
Ventilator Associated Pneumonia incidence
Time frame: Up to 28 days after inclusion
Incidence of any kind of nosocomial infection
Time frame: Up to 28 days after inclusion
Ventilator Associated Tracheabronchitis incidence
Time frame: Up to 28 days after inclusion
Time frame: Up to 28 days after inclusion
Days of intubation with study tube
Time frame: Up to 28 days after inclusion
Time frame: Up to 60 days after inclusion
Time frame: Up to 28 days after inclusion
Incidence of tracheal bacterial colonization reaching a CFU Count 10^6 CFU/ml
Time frame: Up to 28 days after inclusion
Ventilator associated Condition and infectious iVAC
Time frame: Up to 28 days of intubation after inclusion
Amount and type of bacteria, resistance pattern
Time frame: Up to 28 days of intubation after inclusion
Bactiguard AB
Industry
VITAL - VAP Prevention in ICU by BACTIGUARD coAting of endotracheaL Tube
Acronym: VITAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07482007
Cross Infection, Disease Attributes
Tanta, Egypt
View Trial DetailsNCT07013032
Cross Infection, Disease Attributes
Konya, Karatay, Turkey (Türkiye)
View Trial DetailsNCT07509697
Artificial Intelligence (AI), Bacterial Infections
Yenimahalle, Ankara, Turkey (Türkiye)
View Trial DetailsNCT04700202
Cross Infection, Disease Attributes
Dallas, Texas, United States
View Trial Details